Search tips
Search criteria 


Logo of aairAllergy, Asthma & Immunology ResearchThis ArticleThis JournalAboutFor Contributorse-Submission
Allergy Asthma Immunol Res. Nov 2012; 4(6): 357–361.
Published online Apr 20, 2012. doi:  10.4168/aair.2012.4.6.357
PMCID: PMC3479230
Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria
Young-Hee Nam,1 Joo-Hee Kim,2 Hyun Jung Jin,1 Eui-Kyung Hwang,1 Yoo-Seob Shin,1 Young-Min Ye,1 and Hae-Sim Parkcorresponding author1
1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
2Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
corresponding authorCorresponding author.
Correspondence to: Hae-Sim Park, MD, PhD, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, San 5 Woncheon-dong, Yeongtong-gu, Suwon 443-721, Korea. Tel: +82-31-219-5196; Fax: +82-31-219-5154; hspark/at/
Young-Hee Nam and Joo-Hee Kim equally contributed to this study as co-first authors.
Received January 19, 2012; Accepted February 10, 2012.
Chronic urticaria (CU) is a common and debilitating disease, and the need for effective treatment has increased. Omalizumab may be an alternative regimen in patients with CU who do not respond to conventional treatments. The aim of this study is to investigate the efficacy and to observe the clinical results of omlizumab in patients with refractory CU.
We conducted a retrospective analysis of 26 patients with refractory CU who were treated with omalizumab. Omalizumab was administered every 2 or 4 weeks, depending on body weight and the total serum IgE level, for 24 weeks.
Fourteen patients (53.8%) achieved remission after the treatment; they had a significantly higher prevalence of personal (P=0.033) and family history of allergic diseases (P=0.002) than those who did not achieve remission. During omalizumab treatment, the urticaria activity score declined significantly (12.11±1.97 to 2.7±4.23; P=0.001) and the CU-quality of life score improved significantly (34.65±13.58 to 60.88±11.11; P=0.004). There were significant decreases in the use of systemic steroids (42.3%-11.5%; P=0.027) and immunomodulators (65.4%-19.2%; P=0.002). The dose of antihistamines required to control CU also decreased significantly (215.66±70.06 to 60.85±70.53 mg/week of loratadine equivalents; P<0.001). No serious adverse event was noted.
These findings suggest that omalizumab can be an effective and safe treatment in patients with refractory CU.
Keywords: Chronic urticaria, refractory, omalizumab
Articles from Allergy, Asthma & Immunology Research are provided here courtesy of
Korean Academy of Asthma, Allergy and Clinical Immunology and Korean Academy of Pediatric Allergy and Respiratory Disease